Name (Synonyms) | Correlation | |
---|---|---|
D001172 | Arthritis, Rheumatoid NIH | 0.38 |
D001168 | Arthritis NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001370 | Rheumatoid arthritis HPO | 0.38 |
HP:0001369 | Arthritis HPO | 0.29 |
There is one clinical trial.
Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.
Description: Realtion between hydroxychloroquine use and COVID-19 infection
Measure: The risk of COVID-19 infection among RA patients Time: 12 weekDescription: Number of cases and number of hospitalization days
Measure: The incidence of hospitalization for Covid-19 patients. Time: 12 week